Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATRANASDAQ:CLLSNASDAQ:GNFTNASDAQ:RCELNASDAQ:VCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$0.70-1.4%$0.72$0.20▼$3.02$83.53M0.692.67 million shs865,826 shsCLLSCellectis$2.49-0.4%$2.63$0.96▼$3.77$138.39M3.1240,396 shs14,710 shsGNFTGenfit$3.45-1.1%$3.58$2.89▼$4.75$171.93M1.0814,880 shs12,609 shsRCELAVITA Medical$8.30-3.2%$14.89$8.01▼$21.70$213.37M1.33212,146 shs251,806 shsVCELVericel$45.45-1.4%$47.44$29.70▼$53.05$2.20B1.71541,221 shs258,209 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-2.08%+1.17%+5.87%+16.19%-74.37%CLLSCellectis-0.40%+0.81%-0.40%-16.16%+30.37%GNFTGenfit+0.15%0.00%-1.99%-9.92%-6.76%RCELAVITA Medical-3.15%-6.43%-48.09%-50.09%-41.09%VCELVericel-1.43%+3.63%-8.29%+6.69%+48.72%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.7498 of 5 stars3.01.00.04.72.62.50.6CLLSCellectis2.4871 of 5 stars3.52.00.00.01.52.51.3GNFTGenfit0.7041 of 5 stars3.52.00.00.00.60.00.0RCELAVITA Medical1.0129 of 5 stars3.42.00.00.01.10.00.6VCELVericel0.4927 of 5 stars1.50.00.00.02.70.81.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics2.00Hold$28.003,901.14% UpsideCLLSCellectis3.00Buy$8.50241.37% UpsideGNFTGenfit3.00Buy$11.00218.84% UpsideRCELAVITA Medical2.80Moderate Buy$27.80234.94% UpsideVCELVericel3.00Buy$46.402.09% UpsideCurrent Analyst RatingsLatest ATRA, RCEL, VCEL, CLLS, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024RCELAVITA MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/26/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/1/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $54.003/1/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$46.00 ➝ $53.002/23/2024RCELAVITA MedicalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.002/23/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$8.57M9.75N/AN/A($0.97) per share-0.72CLLSCellectis$25.73M5.38N/AN/A$2.76 per share0.90GNFTGenfit$28.57M6.02N/AN/A$1.48 per share2.33RCELAVITA Medical$50.14M4.26N/AN/A$1.92 per share4.32VCELVericel$197.52M11.13$0.02 per share2,634.21$4.73 per share9.61Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)CLLSCellectis-$106.14M-$1.67N/AN/AN/A-346.65%-73.03%-32.22%5/2/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)RCELAVITA Medical-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/13/2024 (Confirmed)VCELVericel-$3.18M-$0.09N/A90.90N/A-1.61%-1.55%-1.02%5/8/2024 (Confirmed)Latest ATRA, RCEL, VCEL, CLLS, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2024N/ARCELAVITA Medical-$0.26N/A+$0.26N/AN/AN/A 5/8/2024N/AVCELVericel-$0.11N/A+$0.11N/AN/AN/A 3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million2/29/2024Q4 2023VCELVericel$0.18$0.26+$0.08$0.26$64.28 million$65.00 million 2/22/2024Q4 2023RCELAVITA Medical-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.720.65CLLSCellectis0.572.202.20GNFTGenfit0.922.942.94RCELAVITA Medical0.817.887.46VCELVericelN/A4.494.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CLLSCellectis63.90%GNFTGenfit2.24%RCELAVITA Medical27.66%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.50%CLLSCellectis16.41%GNFTGenfit4.20%RCELAVITA Medical1.96%VCELVericel5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableCLLSCellectis23155.58 million46.46 millionOptionableGNFTGenfit15949.84 million47.74 millionNot OptionableRCELAVITA Medical20725.71 million25.20 millionOptionableVCELVericel31448.38 million45.86 millionOptionableATRA, RCEL, VCEL, CLLS, and GNFT HeadlinesSourceHeadlineNew York State Common Retirement Fund Sells 30,717 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 25 at 8:29 AMVericel to Report First-Quarter 2024 Financial Results on May 8, 2024globenewswire.com - April 24 at 8:30 AMFederated Hermes Inc. Has $19.96 Million Stock Position in Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 22 at 5:56 AMVericel Corporation (VCEL) stock historical prices & data – Yahoo Financenz.finance.yahoo.com - April 21 at 11:52 PMDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stockinsidertrades.com - April 21 at 4:32 AMVericel Co. (NASDAQ:VCEL) CEO Sells $780,325.00 in Stockinsidertrades.com - April 20 at 7:12 AMVericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 Sharesmarketbeat.com - April 19 at 6:44 PMKnights of Columbus Asset Advisors LLC Purchases 112,169 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 19 at 1:38 PMVericel Corpmoney.usnews.com - April 17 at 9:10 PMMutual of America Capital Management LLC Sells 21,706 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 15 at 5:51 AMVericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Evenfinance.yahoo.com - April 13 at 1:24 PMVericel Co. (NASDAQ:VCEL) Sees Large Increase in Short Interestmarketbeat.com - April 12 at 10:31 AMVericel Co. (NASDAQ:VCEL) Shares Acquired by Conestoga Capital Advisors LLCmarketbeat.com - April 10 at 3:55 PMVericel Co. (NASDAQ:VCEL) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - April 8 at 4:13 AMCommit To Buy Vericel At $25, Earn 9% Annualized Using Optionsnasdaq.com - April 7 at 10:47 PMVericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Sharesinsidertrades.com - March 30 at 7:35 AMVericel Co. (NASDAQ:VCEL) Stock Holdings Decreased by SG Americas Securities LLCmarketbeat.com - March 30 at 4:17 AMVericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40marketbeat.com - March 27 at 11:23 AMAnalyst Scoreboard: 5 Ratings For Vericelmarkets.businessinsider.com - March 27 at 1:54 AMTruist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)marketbeat.com - March 26 at 9:35 AMVericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in Stockinsidertrades.com - March 14 at 9:39 AMVericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in Stockinsidertrades.com - March 12 at 4:46 AMVCEL Oct 2024 50.000 callca.finance.yahoo.com - March 3 at 7:05 PMUS$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Resultsfinance.yahoo.com - March 3 at 9:03 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Asian benchmarks mostly climb despite worries about US economyApril 25, 2024 2:14 AMView Stock market today: Asian benchmarks mostly climb despite worries about US economy3 Companies Buying Back Stock Before New HighsApril 1, 2024 6:05 AMView 3 Companies Buying Back Stock Before New HighsUnited Parcel Service Is Setting Up for Another FallApril 24, 2024 6:15 AMView United Parcel Service Is Setting Up for Another FallAmazon Stock Insights & Analysis for 2024 April 22, 2024 7:13 AMView Amazon Stock Insights & Analysis for 2024 All Headlines Company DescriptionsAtara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.AVITA MedicalNASDAQ:RCELAVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.VericelNASDAQ:VCELVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.